Metrics to compare | 229000 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship229000PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.1x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.4x | 2.6x | |
Price / LTM Sales | 0.0x | 3.1x | 3.1x | |
Upside (Analyst Target) | 0.0% | 39.4% | 53.0% | |
Fair Value Upside | Unlock | 23.2% | 5.9% | Unlock |
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.